<DOC>
	<DOCNO>NCT00188136</DOCNO>
	<brief_summary>Karyotype major prognostic risk factor patient acute myeloid leukemia ( AML ) translate unfavourable outcome case poor-risk cytogenetic aberration . Several study show allogeneic hematopoietic stem cell transplantation ( HSCT ) myeloablative condition rather autologous HSCT consolidation chemotherapy result long-term disease control group patient achieve first complete remission . Nevertheless , complete remission rate achievable significantly low patient favourable risk profile . In fact , minority AML patient poor-risk cytogenetics , although suitable donor , proceed HSCT due refractory disease infectious complication induction chemotherapy ( IC ) . Further , new data show course therapy estimate early two week initiation first course IC patient present 10 % marrow blast significantly bad good clearance blast . As result , chance obtain durable remission considerably low patient bad-risk cytogenetics failure achieve blast clearance proceed allogeneic approach . Together data indicate early treatment intensification warrant order provide potential curative benefit allogeneic HSCT majority high-risk AML patient . We show reduced-intensity conditioning ( RIC ) follow allogeneic PBSC apply aplasia first cycle IC newly-diagnosed high-risk AML patient feasible result sustain disease control . These data prompt u evaluate prospective trial early `` up-front HSCT '' patient newly-diagnosed high-risk AML define karyotype insufficient blast clearance first cycle IC . The goal provide allogeneic HSCT early possible diagnosis AML patient .</brief_summary>
	<brief_title>Early Allogeneic Blood Stem Cell Transplantation High-risk Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description>Only patient newly-diagnosed AML eligible prospective study . An immediate donor-search , either within family volunteer donor registry , perform diagnosis irrespective expect risk profile . All patient receiv least one cycle IC . Inclusion criteria early allogeneic transplantation either poor risk cytogenetics and/or bad response first cycle IC define 10 % marrow blast day 15 . If patient meet one criterion could enter early allogeneic HSCT trial provide informed consent . DNA-based HLA-typing donor recipient perform use high resolution ( 4 digit ) HLA - A , B , DRB1 DQB1 intermediate resolution ( 2 digit ) HLA- C. During IC-induced aplasia 1st 2nd cycle fludarabine-based reduced intensity conditioning therapy start donor available . All patient receive fludarabine 30 mg/m2 i.v . daily five day ( day- 6 -2 ) melphalan 150 mg/mÂ² day-2 . Antithymocyte globulin ( ATG Fresenius 10 mg/kg/day day -5 -2 , total dose 40 mg/kg , Fresenius , Bad Homburg , Germany ) apply transplantation unrelated HLA mismatch family donor . PBSC graft prefer . As immunosuppression cyclosporin A ( CsA ) either administer intravenously dose 3 mg/kg/day give bioequivalent amount oral formulation two divide dos start day blood stem cell infusion ( day -1 ) . The dose CsA adjust maintain blood level 150 250 ng/ml . Starting day 50 , oral CsA administration taper 5 % weekly GVHD inactive . Acute chronic GvHD treat prednisone , CsA tacrolimus .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>newlydiagnosed AML either poor risk cytogenetics and/or bad response first cycle IC define 10 % marrow blast day 15 HLAcompatible donor ( maximum one HLAantigen mismatch ) donor Age &lt; 16 year &gt; 75 year Cardiac insufficiency require treatment symptomatic coronary artery disease Hepatic disease , AST &gt; 2 time normal Severe hypoxemia , pO2 &lt; 70 mm Hg , decrease DLCO &lt; 70 % predict ; mild hypoxemia , pO2 &lt; 80 mm Hg severely decrease DLCO &lt; 60 % predict Impaired renal function ( creatinine &gt; 2 time normal creatinine clearance &lt; 50 % age , weight , height ) HIVpositive patient due risk reactivation acceleration HIV replication Female patient pregnant breast feeding due risk fetus condition regimen potential risk nurse infant Life expectancy severely limited disease malignancy</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>AML , allogeneic transplantation , high-risk , karyotype</keyword>
</DOC>